Sofiva Genomics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 04, 2022 at 04:46 am IST
Share
Sofiva Genomics Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 129.64 million compared to TWD 133.25 million a year ago. Net income was TWD 5.92 million compared to TWD 19.69 million a year ago. Basic earnings per share from continuing operations was TWD 0.28 compared to TWD 0.93 a year ago. Diluted earnings per share from continuing operations was TWD 0.28 compared to TWD 0.92 a year ago.
For the six months, sales was TWD 255.35 million compared to TWD 257.84 million a year ago. Net income was TWD 20.23 million compared to TWD 28.6 million a year ago. Basic earnings per share from continuing operations was TWD 0.95 compared to TWD 1.35 a year ago. Diluted earnings per share from continuing operations was TWD 0.95 compared to TWD 1.34 a year ago.
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.
SOFIVA GENOMICS CO.,LTD. 
